Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
47 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Bone Fracture - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Bone Fracture - Pipeline Review, H2 2014', provides an overview of the Bone Fracture's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Bone Fracture, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Fracture and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Bone Fracture - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bone Fracture and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bone Fracture products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bone Fracture pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bone Fracture - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bone Fracture pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Bone Fracture Overview 6 Therapeutics Development 7 Pipeline Products for Bone Fracture - Overview 7 Pipeline Products for Bone Fracture - Comparative Analysis 8 Bone Fracture - Therapeutics under Development by Companies 9 Bone Fracture - Therapeutics under Investigation by Universities/Institutes 10 Bone Fracture - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Bone Fracture - Products under Development by Companies 13 Bone Fracture - Products under Investigation by Universities/Institutes 14 Bone Fracture - Companies Involved in Therapeutics Development 15 AstraZeneca PLC 15 Biogenomics Limited 16 Bone Therapeutics SA 17 Juventas Therapeutics, Inc. 18 Kaken Pharmaceutical Co., Ltd. 19 Laboratorios SALVAT S.A. 20 TissueGene, Inc. 21 Bone Fracture - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 ALLOB - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 AZD-2858 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 denosumab biosimilar - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 dibotermin alfa - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Gene Therapy for Bone Fracture - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 JVS-200 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 KCB-1B - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 LWnt-3a - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Stem Cell Therapy for Bone Regeneration - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 TG-B - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Bone Fracture - Recent Pipeline Updates 43 Bone Fracture - Dormant Projects 44 Bone Fracture - Discontinued Products 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 47 Disclaimer 47
List of Tables Number of Products under Development for Bone Fracture, H2 2014 7 Number of Products under Development for Bone Fracture - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Bone Fracture - Pipeline by AstraZeneca PLC, H2 2014 15 Bone Fracture - Pipeline by Biogenomics Limited, H2 2014 16 Bone Fracture - Pipeline by Bone Therapeutics SA, H2 2014 17 Bone Fracture - Pipeline by Juventas Therapeutics, Inc., H2 2014 18 Bone Fracture - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2014 19 Bone Fracture - Pipeline by Laboratorios SALVAT S.A., H2 2014 20 Bone Fracture - Pipeline by TissueGene, Inc., H2 2014 21 Assessment by Monotherapy Products, H2 2014 22 Number of Products by Stage and Target, H2 2014 24 Number of Products by Stage and Mechanism of Action, H2 2014 26 Number of Products by Stage and Route of Administration, H2 2014 28 Number of Products by Stage and Molecule Type, H2 2014 30 Bone Fracture Therapeutics - Recent Pipeline Updates, H2 2014 43 Bone Fracture - Dormant Projects, H2 2014 44 Bone Fracture - Discontinued Products, H2 2014 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.